GB Patent

GB2515312A — The use of phytocannabinoids in the treatment of ovarian carcinoma

Assigned to GW Pharma Ltd · Expires 2014-12-24 · 11y expired

What this patent protects

Phytocannabinoids for use in the treatment of ovarian cancer, wherein preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetr…

USPTO Abstract

Phytocannabinoids for use in the treatment of ovarian cancer, wherein preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV) and combinations thereof. Preferably the phytocannabinoid is CBG or the combination of CBG with CBD or the combination of CBD with THCV. The phytocannabinoid may be in the form of an extract or botanical drug substance.

Drugs covered by this patent

Patent Metadata

Patent number
GB2515312A
Jurisdiction
GB
Classification
—
Expires
2014-12-24
Drug substance claim
No
Drug product claim
No
Assignee
GW Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.